Corcept Therapeutics
CORT
212 hedge funds and large institutions have $1.45B invested in Corcept Therapeutics in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 66 increasing their positions, 68 reducing their positions, and 32 closing their positions.
78% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 32
12% more funds holding
Funds holding: 190 → 212 (+22)
10% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $9.82M
3% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 68
1.33% less ownership
Funds ownership: 77.88% → 76.55% (-1.3%)
10% less capital invested
Capital invested by funds: $1.61B → $1.45B (-$159M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.9M |
| 2 |
NC
Nexthera Capital
New York
|
+$19.4M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.3M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$8.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$23.4M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$17.1M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$12.7M |
| 4 |
TA
Teachers Advisors
New York
|
-$11.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.5M |
CORT Hedge Fund Activity: Q1 2018 in Review
212 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2018, worth a combined $1.45B — down 9.9% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new CORT positions and 32 closed out — a net gain of 25 holders — while 66 added to existing stakes and 68 trimmed.
The largest buyer was BlackRock, adding an estimated $27.9M. The largest seller was Prudential Financial, cutting an estimated $23.4M.
- 212 institutional investors held Corcept Therapeutics (CORT) as of Q1 2018, up from 190 in Q4 2017.
- Funds reported $1.45B of Corcept Therapeutics stock for Q1 2018, down 9.9% quarter-over-quarter.
- 57 funds opened new Corcept Therapeutics positions in Q1 2018 and 32 closed out, a net change of +25 holders.
- The largest Corcept Therapeutics buyer in Q1 2018 was BlackRock, an estimated $27.9M added.
- The largest Corcept Therapeutics seller in Q1 2018 was Prudential Financial, an estimated $23.4M sold.
Based on aggregated 13F filings for Q1 2018.